After surgical resection of the liver cancer, adjuvant therapy may prevent recurrence.

Published Date: 19 Apr 2023

The findings showed that after surgical resection or ablation, patients with hepatocellular carcinoma (HCC) who received adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) had a higher rate of recurrence-free survival.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot